Video originally created by FDA -- posted by Lawsuit.com on March 10, 2009

Celgene is alerting healthcare professionals of an increased mortality risk among certain elderly patients treated with Innohep (tinzaparin sodium injection). Innohep is a low-molecular weight heparin that is used along with warfarin to treat acute symptomatic deep vein thrombosis with or without pulmonary embolism.

Results of a controlled clinical study conducted in Europe suggest that elderly patients with kidney dysfunction may have a greater risk of death when treated with Innohep than comparable patients treated with unfractionated heparin. In a July 2008 letter, Celgene had highlighted this risk for patients who are 90 years and older, but the company has now changed the labeling to indicate that these risks apply to patients with kidney dysfunction who are 70 and older. The company says to consider alternatives to Innohep when treating these patients.

Tags: Celegene, Deep Vein Thrombosis, Elderly, FDA, Heparin, Increased Mortality Risk, Inohep, Kidney Disfunction, Patient Safety, Warfarin

This entry was posted on Thursday, March 12th, 2009 at 3:07 pm and is filed under Consumer Awareness, FDA Information, Heparin, Personal Injury Lawsuit, Pharmaceutical Lawsuits, Product Liability Lawsuit. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.